Cargando…

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice

We investigated first-line (1L) treatment patterns and predictors of taxane use to better understand the evolving metastatic triple-negative breast cancer (mTNBC) treatment landscape. This retrospective analysis of the Truven Health MarketScan(®) (Somers, NY, USA) Database included women with mTNBC...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Shaughnessy, Joyce, Emens, Leisha A., Chui, Stephen Y., Wang, Wei, Russell, Kenneth, Lin, Shih-Wen, Avile, Carlos Flores, Luhn, Patricia, Schneeweiss, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293053/ https://www.ncbi.nlm.nih.gov/pubmed/34287291 http://dx.doi.org/10.3390/curroncol28040239

Ejemplares similares

The hedgehog pathway in triple‐negative breast cancer
por: Habib, Joyce G., et al.
Publicado: (2016)

A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition
por: Arulraj, Theinmozhi, et al.
Publicado: (2023)

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer
por: Tan, Antoinette R., et al.
Publicado: (2023)

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
por: Emens, Leisha A, et al.
Publicado: (2021)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2022)

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
por: Molinero, Luciana, et al.
Publicado: (2019)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

The role of taxanes in triple-negative breast cancer: literature review
por: Mustacchi, Giorgio, et al.
Publicado: (2015)

Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies
por: O’Shaughnessy, Joyce, et al.
Publicado: (2015)

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2021)

The role of taxanes in triple-negative breast cancer: literature review [Corrigendum]
Publicado: (2015)

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
por: Huang, Min, et al.
Publicado: (2022)

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021)

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
por: O’Shaughnessy, Joyce, et al.
Publicado: (2022)

Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
por: Petrelli, Fausto, et al.
Publicado: (2022)

It’s TIME for a biomarker-driven approach to cancer immunotherapy
por: Emens, Leisha A.
Publicado: (2016)

Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer
por: Chou, Ching-Wen, et al.
Publicado: (2021)

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
por: Emens, L.A., et al.
Publicado: (2020)

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Taxanes for the Treatment of Metastatic Breast Cancer
por: Gradishar, W.J.
Publicado: (2012)

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
por: Gluz, Oleg, et al.
Publicado: (2020)

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
por: Carey, Lisa A., et al.
Publicado: (2022)

Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer
por: Emens, Leisha A., et al.
Publicado: (2015)

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
por: Wang, Junbin, et al.
Publicado: (2017)

Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer
por: Giordano, Antonio, et al.
Publicado: (2019)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
por: Yardley, D A, et al.
Publicado: (2018)

Optimal use of taxanes in metastatic breast cancer
por: King, K.M., et al.
Publicado: (2009)

Taxanes in the elderly patient with metastatic breast cancer
por: Yardley, Denise A
Publicado: (2015)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Targeting adenosine for cancer immunotherapy
por: Leone, Robert D., et al.
Publicado: (2018)

Role of Taxanes in Triple-Negative Breast Cancer: A Study From Tertiary Cancer Center in South India
por: Lakshmaiah, K.C., et al.
Publicado: (2017)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
por: Tan, Antoinette R., et al.
Publicado: (2022)

nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis
por: O’Shaughnessy, Joyce, et al.
Publicado: (2013)

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
Publicado: (2019)

Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer
por: Mi, Haoyang, et al.
Publicado: (2020)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2007)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_s5qs7l8ba4l96fq5r8lrnu1g45